Literature DB >> 12368359

Comparative analysis of anti-hepatitis C virus activity and gene expression mediated by alpha, beta, and gamma interferons.

I Wayne Cheney1, Vicky C H Lai, Weidong Zhong, Tessa Brodhag, Shannon Dempsey, Charmaine Lim, Zhi Hong, Johnson Y N Lau, Robert C Tam.   

Abstract

A direct comparison of the inhibitory effects of alpha, beta, and gamma interferons (IFNs) on replication of a hepatitis C virus subgenomic replicon in a hepatoma cell line revealed similarities in antiviral potency. However, alternate IFN-induced antiviral mechanisms were suggested following observations of striking differences between IFN-gamma and IFN-alpha/beta with respect to strength and durability of the antiviral response and the magnitude and pattern of IFN-mediated gene expression.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12368359      PMCID： PMC136623          DOI： 10.1128/jvi.76.21.11148-11154.2002

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  25 in total

1.  Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome.

Authors:  Q L Choo; G Kuo; A J Weiner; L R Overby; D W Bradley; M Houghton
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

2.  DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection.

Authors:  C B Bigger; K M Brasky; R E Lanford
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

3.  Inhibition of hepatitis B virus replication by interferon requires proteasome activity.

Authors:  Michael D Robek; Stefan F Wieland; Francis V Chisari
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

4.  Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial.

Authors:  G L Davis; L A Balart; E R Schiff; K Lindsay; H C Bodenheimer; R P Perrillo; W Carey; I M Jacobson; J Payne; J L Dienstag
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

5.  Effect of alpha interferon on the hepatitis C virus replicon.

Authors:  J T Guo; V V Bichko; C Seeger
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

Review 6.  Antiviral actions of interferons.

Authors:  C E Samuel
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

7.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

8.  Interferon-alpha inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway.

Authors:  Michael Frese; Thomas Pietschmann; Darius Moradpour; Otto Haller; Ralf Bartenschlager
Journal:  J Gen Virol       Date:  2001-04       Impact factor: 3.891

9.  Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations.

Authors:  N Krieger; V Lohmann; R Bartenschlager
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

10.  Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs.

Authors:  Michael Frese; Verena Schwärzle; Kerstin Barth; Nicole Krieger; Volker Lohmann; Sabine Mihm; Otto Haller; Ralf Bartenschlager
Journal:  Hepatology       Date:  2002-03       Impact factor: 17.425
View more
  30 in total

1.  Synergistic in vitro interactions between alpha interferon and ribavirin against bovine viral diarrhea virus and yellow fever virus as surrogate models of hepatitis C virus replication.

Authors:  Victor E Buckwold; Jiayi Wei; Michelle Wenzel-Mathers; Julie Russell
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

Review 2.  Stealth and cunning: hepatitis B and hepatitis C viruses.

Authors:  Stefan F Wieland; Francis V Chisari
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

3.  T cell-dependent production of IFN-gamma by NK cells in response to influenza A virus.

Authors:  Xiao-Song He; Monia Draghi; Kutubuddin Mahmood; Tyson H Holmes; George W Kemble; Cornelia L Dekker; Ann M Arvin; Peter Parham; Harry B Greenberg
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

Review 4.  Organ system view of the hepatic innate immunity in HCV infection.

Authors:  Bo-Ram Bang; Sandra Elmasry; Takeshi Saito
Journal:  J Med Virol       Date:  2016-05-13       Impact factor: 2.327

5.  Increased protection from vaccinia virus infection in mice genetically prone to lymphoproliferative disorders.

Authors:  Mina O Seedhom; Keisha S Mathurin; Sung-Kwon Kim; Raymond M Welsh
Journal:  J Virol       Date:  2012-03-21       Impact factor: 5.103

6.  Cytopathic and noncytopathic interferon responses in cells expressing hepatitis C virus subgenomic replicons.

Authors:  Ju-Tao Guo; Qing Zhu; Christoph Seeger
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

7.  Evaluation of a DNA vaccine candidate co-expressing GP3 and GP5 of porcine reproductive and respiratory syndrome virus (PRRSV) with interferon α/γ in immediate and long-lasting protection against HP-PRRSV challenge.

Authors:  Yijun Du; Jing Qi; Yu Lu; Jiaqiang Wu; Dongwan Yoo; Xing Liu; Xiumei Zhang; Jun Li; Wenbo Sun; Xiaoyan Cong; Jianli Shi; Jinbao Wang
Journal:  Virus Genes       Date:  2012-07-28       Impact factor: 2.332

8.  SH2 modified STAT1 induces HLA-I expression and improves IFN-γ signaling in IFN-α resistant HCV replicon cells.

Authors:  Bret Poat; Sidhartha Hazari; Partha K Chandra; Feyza Gunduz; Luis A Balart; Xavier Alvarez; Srikanta Dash
Journal:  PLoS One       Date:  2010-09-30       Impact factor: 3.240

9.  Induction of MxA gene expression by influenza A virus requires type I or type III interferon signaling.

Authors:  Dirk Holzinger; Carl Jorns; Silke Stertz; Stéphanie Boisson-Dupuis; Robert Thimme; Manfred Weidmann; Jean-Laurent Casanova; Otto Haller; Georg Kochs
Journal:  J Virol       Date:  2007-05-09       Impact factor: 5.103

10.  Enhanced antiviral activity against foot-and-mouth disease virus by a combination of type I and II porcine interferons.

Authors:  Mauro Pires Moraes; Teresa de Los Santos; Marla Koster; Traci Turecek; He Wang; Vladimir G Andreyev; Marvin J Grubman
Journal:  J Virol       Date:  2007-04-25       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.